Case report: Multidrug-resistant cytomegalovirus in a modified multivisceral transplant recipient

Transplantation

Volumn 93, Issue 7, 2012, Pages

  Goldsmith, Petra M ^a   Husain, Mir Mubariz ^a   Carmichael, Andrew ^a   Zhang, Hongyi ^a   Middleton, Stephen J ^a  

^a CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CIDOFOVIR; FOSCARNET; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; LEFLUNOMIDE; METHYLPREDNISOLONE; PREDNISOLONE; TACROLIMUS; VALGANCICLOVIR;

ABDOMINAL FIBROMATOSIS; ACUTE GRAFT REJECTION; ADULT; ANTIVIRAL RESISTANCE; CASE REPORT; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FAMILIAL COLON POLYPOSIS; FEMALE; FOLLOW UP; GENE MUTATION; GENOTYPE; HOSPITAL READMISSION; HUMAN; INTESTINE BIOPSY; INTESTINE TRANSPLANTATION; KIDNEY TRANSPLANTATION; LETTER; LYMPHOCYTOPENIA; MULTIDRUG RESISTANCE; NONHUMAN; OBSTRUCTIVE UROPATHY; ORGAN TRANSPLANTATION; PANCREAS TRANSPLANTATION; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SENSORY NEUROPATHY; SEROCONVERSION; STOMACH TRANSPLANTATION; SUPERIOR CAVA VEIN; SUPERIOR CAVA VEIN THROMBOSIS; UL97 GENE; VEIN THROMBOSIS; VIREMIA; VIRUS GENE; VIRUS LOAD; VIRUS REACTIVATION;

ADULT; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CYTOSINE; DRUG RESISTANCE, MULTIPLE, VIRAL; FEMALE; FOSCARNET; GANCICLOVIR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTESTINE, SMALL; ISOXAZOLES; KIDNEY TRANSPLANTATION; PANCREAS TRANSPLANTATION; PHOSPHONIC ACIDS; RECURRENCE; STOMACH; TREATMENT OUTCOME;

EID: 84859240987     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318249b163     Document Type: Letter

References (11)

1. Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89: 779
2. Sudarsanam T, Sahni RD, John GT. Leflunomide: A possible alternative for gangciclovir sensitive and resistant cytomegalovirus infections. Postgrad Med J 2006; 82: 313
3. Avery RK, Mossad SB, Poggio E, et al. Utility of leflunomide in the treatment of complex cytomegalovirus syndromes. Transplantation 2010; 90: 419
4. Limaye AP, Corey L, Koelle DM, et al. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000; 356: 645
5. Baldanti F, Lurain N, Gerna G. Clinical and biologic aspects of human cytomegalovirus resistance to antiviral drugs. Hum Immunol 2004; 65: 403
6. Abu-Elmagd K, Reyes J, Todo S, et al. Clinical intestinal transplantation: New perspectives and immunologic considerations. J Am Coll Surg 1998; 186: 512
7. Thompson JS. Intestinal transplantation. Experience in the United States. Eur J Pediatr Surg 1999; 9: 271
8. Schreiber A, Harter G, Schubert A, et al. Antiviral treatment of cytomegalovirus infection and resistant strains. Expert Opin Pharmacother 2009; 10: 191
9. Eid AJ, Arthurs SK, Deziel PJ, et al. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: Therapeutic implications and outcomes. Clinical Transplant 2008; 22: 162
10. Biron KK, Harvey RJ, Chamberlain SC, et al. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob Agents Chemother 2002; 46: 2365
11. Avery RK, Marty FM, Strasfeld L, et al. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients. Transpl Infect Dis 2010; 12: 489.